Joaquin de Rojas, MD
Ophthalmology · Venice, FLNPI 1619387370
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 40.9% of the total. 2025 is the largest year on record at $54,612, more than ten times the $710 reported in 2019. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $442.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$66K
- Lensar, Inc.$32K
- Johnson & Johnson Surgical Vision, Inc.$22K
- Carl Zeiss Meditec, Inc.$13K
- Nordic Pharma, Inc.$12K
- AbbVie$6K
- plus $11K from 23 others
Across 8 payments — averaging $35,489 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$284K
What the payments were for
- Consulting fees$74,26546%
- Speaking & faculty fees$61,23338%
- Travel & lodging$8,2875%
- Food & beverage$17,19011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 97 | $65,897 |
| Lensar, Inc. | 16 | $32,494 |
| Johnson & Johnson Surgical Vision, Inc. | 57 | $21,813 |
| Carl Zeiss Meditec, Inc. | 13 | $12,515 |
| Nordic Pharma, Inc. | 2 | $11,909 |
| AbbVie(2 entities) | 32 | $5,555 |
| Rxsight Inc | 11 | $3,503 |
| Alcon | 21 | $2,487 |
| Tearlab Corp | 2 | $1,121 |
| Bausch & Lomb Americas Inc. | 39 | $873 |
| Tarsus Pharmaceuticals, Inc. | 12 | $487 |
| Dompe US, Inc. | 10 | $429 |
| Harrow Eye, LLC | 13 | $399 |
| Glaukos Corporation | 6 | $362 |
| Oyster Point Pharma, Inc. | 3 | $188 |
| Novartis | 7 | $173 |
| Amgen | 1 | $123 |
| Apellis Pharmaceuticals, Inc. | 1 | $106 |
| Sight Sciences, Inc. | 6 | $104 |
| Ocular Therapeutix, Inc. | 4 | $97 |
| Dutch Ophthalmic, USA | 2 | $87 |
| Johnson & Johnson Vision Care, Inc. | 1 | $55 |
| Halozyme Inc | 2 | $46 |
| Carl Zeiss Meditec USA, Inc. | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Biotissue Holdings Inc. | 1 | $25 |
| Beaver-visitec International, Inc. | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Oasis Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$75,901
- CEQUA$64,661
- LENSAR LASER SYSTEM$32,462
- Lacrifill$11,909
- VERACITY SURGICAL$4,870
- IOLMaster 700$4,790
- ARTEVO 800$3,850
- CIRRUS HD-OCT$3,570
- RXSIGHT CONTACT LENS$3,338
- RXSIGHT INJECTOR CARTRIDGE$3,338
- RXSIGHT INJECTOR HANDPIECE$3,338
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,338
- LIGHT ADJUSTABLE LENS (LAL)$3,338
- CALLISTO eye$2,550
- VisuMax$2,550
- QUATERA 700$2,120
- ATLAS 500$2,120
- MEL 90$2,040
- ILUX$1,719
- VUITY$1,556
How this compares
$160,975 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CequaCyclosporine | 70 | $64,123 |
| XdemvyLotilaner | 21 | $40,723 |
| RestasisCyclosporine | 32 | $32,351 |
| Prednisolone Acetate | 723 | $29,701 |
| VevyeCyclosporine | 17 | $12,789 |
| MoxifloxacinMoxifloxacin Hcl | 578 | $11,747 |
| MieboPerfluorohexyloctane/Pf | 15 | $11,211 |
| XiidraLifitegrast | 13 | $10,311 |
| Cyclosporine | 12 | $9,215 |
| Ketorolac Tromethamine | 576 | $8,406 |
| Lotemax SmLoteprednol Etabonate | 17 | $4,261 |
| ProlensaBromfenac Sodium | 11 | $3,733 |
| Bromfenac Sodium | 16 | $2,352 |
| Loteprednol Etabonate | 13 | $2,032 |
| ValacyclovirValacyclovir Hcl | 65 | $2,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sun Pharmaceutical Industries Inc.Cequa | $65,897 | $64,12370 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $487 | $40,72321 claims |
| AbbVieRestasis | $5,555 | $32,35132 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $873 | $21,52328 claims |
| Harrow Eye, LLCVevye | $399 | $12,78917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Venice
- Patricia StephensonVenice$451K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.